SCHOTT Pharma
€24.55Change from previous close: +0.82%Absolute change: +€0.20
At a glance
- Revenue growth
- +3.04%
- FY to Sep 2025 vs FY to Sep 2024
- Net income growth
- −2.16%
- FY to Sep 2025 vs FY to Sep 2024
- Net margin
- 14.9%
- FY to Sep 2024: 15.6%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 1,694 | 1,610 | 1,628 | 1,599 | 1,528 | — |
| Current assets | 722 | 669 | 699 | 681 | 648 | — |
| Cash and equivalents | 24.9 | 27.8 | 24.6 | 22.5 | 28.3 | — |
| Short-term investments | 15.0 | 4.5 | 7.5 | 3.2 | 12.9 | — |
| Inventory | 172 | 181 | 183 | 175 | 167 | — |
| Net property, plant and equipment | 833 | 804 | 792 | 786 | 748 | — |
| Goodwill | — | — | — | 28.4 | — | — |
| Other intangible assets | — | — | — | 1.3 | — | — |
| Long-term investments | 95.9 | 90.8 | 92.4 | 88.5 | 87.3 | — |
| Current liabilities | 449 | 422 | 443 | 454 | 413 | — |
| Accounts payable | 77.7 | 70.8 | 63.8 | 104 | 76.8 | — |
| Total debt | — | — | — | 83.0 | — | 84.0 |
| Total liabilities | 696 | 666 | 695 | 705 | 663 | — |
| Total equity (incl. minority) | 998 | 944 | 932 | 894 | 865 | — |
| Minority interest | 2.2 | 1.9 | 2.1 | 2.0 | 1.8 | — |